
Saturday, August 31, 2024 5:49:54 AM
A response to this query...
what is unique about atossa therapeutics inc
Response...
Is Atossa Therapeutics a good buy?
Why is Atossa stock dropping?
Who owns Atossa Therapeutics?
What is the target price for Atossa Genetics?
Stock Price Target ATOS
High $6.25
Median $6.00
Low $4.00
Average $5.42
Current Price $1.39
ATOS | Atossa Therapeutics Inc. Analyst Estimates & Rating - WSJ
WSJ
https://www.wsj.com › quotes › ATOS › research-ratings
Search for: What is the target price for Atossa Genetics?
What is the stock price forecast for Atossa Therapeutics in 2025?
What does Atossa Therapeutics do?
Recent ATOS News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2025 01:00:07 PM
- Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications • GlobeNewswire Inc. • 03/11/2025 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2025 09:05:08 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/07/2025 09:09:11 PM
- Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care • GlobeNewswire Inc. • 02/05/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2025 02:00:09 PM
- Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 • GlobeNewswire Inc. • 01/30/2025 01:17:09 PM
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 • GlobeNewswire Inc. • 01/23/2025 01:15:00 PM
- Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer • GlobeNewswire Inc. • 01/06/2025 02:00:00 PM
- Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/12/2024 01:15:00 PM
- Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density • GlobeNewswire Inc. • 12/11/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2024 02:05:08 PM
- Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/10/2024 02:05:00 PM
- Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research • GlobeNewswire Inc. • 12/09/2024 01:15:00 PM
- Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research • GlobeNewswire Inc. • 11/21/2024 01:30:00 PM
- Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 11/20/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 09:35:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/19/2024 09:30:19 PM
- Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/12/2024 01:30:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/08/2024 07:17:17 PM
- Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development • GlobeNewswire Inc. • 11/05/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 11:35:08 AM
- Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: • GlobeNewswire Inc. • 11/04/2024 11:30:00 AM
- Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 10/31/2024 12:15:00 PM
UAV Corp. to Present Critical Inflation Test in 30 Days, Paving the Way to Secure Over $525 Million in DART Series Sales Contracts • UMAV • Mar 14, 2025 1:00 PM
Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance • FITY • Mar 14, 2025 10:30 AM
WIN-LIGHT GLOBAL FILES SEC SCHEDULE 13G DISCLOSING 1.96M SHARES OF PASSIVE INSTITUTIONAL INVESTOR OWNERSHIP • CNTM • Mar 14, 2025 7:13 AM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM